Minerva Neurosciences, Inc.
NERV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001598646
No open-market purchases or sales by Minerva Neurosciences, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q2 2026, worth $234.8M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Minerva Neurosciences, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 21 | 22 | +1 |
| Shares | 2.12M | 2.09M | −32.1K (−1.5%) |
| Value | $5.65M | $4.63M | −$1.02M (−18.1%) |
New holders (4)
Institutions that held Minerva Neurosciences, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Royal Bank of Canada | 1,545 | $3.00K | 0.00% |
| BNP Paribas Arbitrage, SA | 62 | $138 | 0.00% |
| SBI Securities Co., Ltd. | 53 | $118 | 0.00% |
| JPMorgan Chase & Co | 17 | $38 | 0.00% |
Sold out (3)
Institutions that held Minerva Neurosciences, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Susquehanna International Group, LLP | 20,224 | $54.0K |
| Russell Investments Group, Ltd. | 1,175 | $3.14K |
| Barclays PLC | 3 | $8 |